Gilead teams up with insitro for experimental NASH treatments
Gilead Sciences Inc said on Tuesday it will partner with privately held insitro to develop therapies for a fatty liver disease called non-alcoholic steatohepatitis (NASH), as the drugmaker tries to overcome its recent setback in developing NASH treatments.
from Reuters: Health News https://reut.rs/2ICVaXp
http://bit.ly/2zwRqiM